Review
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2012; 18(48): 7141-7148
Published online Dec 28, 2012. doi: 10.3748/wjg.v18.i48.7141
Table 2 Differences in B cell depletion therapies in primary biliary cirrhosis murine models
ResultsModelTherapy (time)
AmeliorationNOD.c3c4 miceIgμ knockout
dnTGF-βRII miceAnti-CD20 (4-6 wk)
Exacerbation2OA-BSA-induced miceAnti-CD20/Anti-CD79 (6 wk)
dnTGF-βRII miceIgμ knockout
No effectdnTGF-βRII miceAnti-CD20 (20-22 wk)